A holistic approach to inflammation research.
The current understanding of inflammatory dysregulation shared across many organs, systems and diseases means that single organ-based symptom relief is insufficient. It is key for you to harness a more holistic approach to inflammation drug development, addressing the imbalance between immune activation and control.
By doing this, you target disease modification instead of symptom alleviation, which has tremendous future implications as over 80 chronic immune-mediated inflammatory diseases (IMIDs) share similar molecular pathways.
Harness our scientific expertise and experience in bringing inflammation therapies to market, enabling you to extend the reach and bring benefit to more patients.
Maximize the return on your product.
The interconnected nature of inflammatory diseases creates complexity within inflammation research, but also the opportunity for a high return on investment for successful therapeutic agents.
For this strategic approach, you need a single partner that can screen novel agents in multiple inflammatory diseases. We offer extensive preclinical and clinical expertise to help identify and advance your novel agents, whether they are new chemical entities (NCEs), biologics, biosimilars or stem cells.
High-quality data and low-risk trials, wherever you are.
Progressing your new therapy into trials requires you to find the right patients and the most suitable sites, which are often found all over the world. To support your global study plan, you need a partner with a global footprint.
At any one time, our Central Laboratory Services works on over 40% of clinical trials worldwide. Insights gained from the data collected, which is housed in a central knowledgebase, allow us to strategically address your clinical trial needs. You can also leverage Labcorp data by using Xcellerate® Trial Design to pressure test trial protocols, identify optimal sites and target specific patient populations. Our worldwide pool of expertise allows centralized assessment of trial endpoints and ongoing test results, wherever your trial sites are, yielding consistent analyses and data you can rely on.